161 related articles for article (PubMed ID: 36805500)
1. Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction.
Selvanesan BC; Varghese S; Andrys-Olek J; Arriaza RH; Prakash R; Tiwari PB; Hupalo D; Gusev Y; Patel MN; Contente S; Sanda M; Uren A; Wilkerson MD; Dalgard CL; Shimizu LS; Chruszcz M; Borowski T; Upadhyay G
Cancer Lett; 2023 Apr; 558():216094. PubMed ID: 36805500
[TBL] [Abstract][Full Text] [Related]
2. Small Molecule Binds with Lymphocyte Antigen 6K to Induce Cancer Cell Death.
Benti S; Tiwari PB; Goodlett DW; Daneshian L; Kern GB; Smith MD; Uren A; Chruszcz M; Shimizu LS; Upadhyay G
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32098321
[TBL] [Abstract][Full Text] [Related]
3. Development of fluorophore labeled or biotinylated anticancer small molecule NSC243928.
Prakash R; Goodlett DW; Varghese S; Andrys J; Gbadamosi FA; Arriaza RH; Patel M; Tiwari PB; Borowski T; Chruszcz M; Shimizu LS; Upadhyay G
Bioorg Med Chem; 2023 Feb; 79():117171. PubMed ID: 36680947
[TBL] [Abstract][Full Text] [Related]
4. Experimental and Computational Studies Reveal Novel Interaction of Lymphocytes Antigen 6K to TGF-β Receptor Complex.
Andrys-Olek J; Selvanesan BC; Varghese S; Arriaza RH; Tiwari PB; Chruszcz M; Borowski T; Upadhyay G
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628960
[TBL] [Abstract][Full Text] [Related]
5. LY6K depletion modulates TGF-β and EGF signaling.
Park S; Park D; Han S; Chung GE; Soh S; Ka HI; Joo HJ; Yang Y
Cancer Med; 2023 Jun; 12(11):12593-12607. PubMed ID: 37076981
[TBL] [Abstract][Full Text] [Related]
6. Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.
AlHossiny M; Luo L; Frazier WR; Steiner N; Gusev Y; Kallakury B; Glasgow E; Creswell K; Madhavan S; Kumar R; Upadhyay G
Cancer Res; 2016 Jun; 76(11):3376-86. PubMed ID: 27197181
[TBL] [Abstract][Full Text] [Related]
7. miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer.
Kim YS; Park SJ; Lee YS; Kong HK; Park JH
Oncotarget; 2016 Jul; 7(27):42261-42273. PubMed ID: 27304060
[TBL] [Abstract][Full Text] [Related]
8. LY6K promotes glioblastoma tumorigenicity via CAV-1-mediated ERK1/2 signaling enhancement.
Sastry NG; Wan X; Huang T; Alvarez AA; Pangeni RP; Song X; James CD; Horbinski CM; Brennan CW; Nakano I; Hu B; Cheng SY
Neuro Oncol; 2020 Sep; 22(9):1315-1326. PubMed ID: 32055849
[TBL] [Abstract][Full Text] [Related]
9. NSC243928 Treatment Induces Anti-Tumor Immune Response in Mouse Mammary Tumor Models.
Selvanesan BC; de Mingo Pulido A; Varghese S; Rohila D; Hupalo D; Gusev Y; Contente S; Wilkerson MD; Dalgard CL; Upadhyay G
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900259
[TBL] [Abstract][Full Text] [Related]
10. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy.
Suda T; Tsunoda T; Daigo Y; Nakamura Y; Tahara H
Cancer Sci; 2007 Nov; 98(11):1803-8. PubMed ID: 17784873
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-500a-3p inhibits cell proliferation and invasion by targeting lymphocyte antigen 6 complex locus K (LY6K) in human non-small cell lung cancer.
Liao XH; Xie Z; Guan CN
Neoplasma; 2018 Sep; 65(5):673-682. PubMed ID: 30249107
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic activation of LY6K predicts the presence of metastasis and poor prognosis in breast carcinoma.
Kong HK; Park SJ; Kim YS; Kim KM; Lee HW; Kang HG; Woo YM; Park EY; Ko JY; Suzuki H; Chun KH; Song E; Jang KY; Park JH
Oncotarget; 2016 Aug; 7(34):55677-55689. PubMed ID: 27494879
[TBL] [Abstract][Full Text] [Related]
13. LY6K-AS lncRNA is a lung adenocarcinoma prognostic biomarker and regulator of mitotic progression.
Ali MM; Di Marco M; Mahale S; Jachimowicz D; Kosalai ST; Reischl S; Statello L; Mishra K; Darnfors C; Kanduri M; Kanduri C
Oncogene; 2021 Apr; 40(13):2463-2478. PubMed ID: 33674747
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K.
Geng L; Wang Z; Tian Y
J Ovarian Res; 2022 Jan; 15(1):1. PubMed ID: 34980214
[TBL] [Abstract][Full Text] [Related]
15. Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome.
Luo L; McGarvey P; Madhavan S; Kumar R; Gusev Y; Upadhyay G
Oncotarget; 2016 Mar; 7(10):11165-93. PubMed ID: 26862846
[TBL] [Abstract][Full Text] [Related]
16. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas.
Ishikawa N; Takano A; Yasui W; Inai K; Nishimura H; Ito H; Miyagi Y; Nakayama H; Fujita M; Hosokawa M; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
Cancer Res; 2007 Dec; 67(24):11601-11. PubMed ID: 18089789
[TBL] [Abstract][Full Text] [Related]
17. LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.
Matsuda R; Enokida H; Chiyomaru T; Kikkawa N; Sugimoto T; Kawakami K; Tatarano S; Yoshino H; Toki K; Uchida Y; Kawahara K; Nishiyama K; Seki N; Nakagawa M
Br J Cancer; 2011 Jan; 104(2):376-86. PubMed ID: 21063397
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer.
Ishikawa H; Imano M; Shiraishi O; Yasuda A; Peng YF; Shinkai M; Yasuda T; Imamoto H; Shiozaki H
Gastric Cancer; 2014 Jan; 17(1):173-80. PubMed ID: 23613128
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A; Clark A; Assayag F; Chateau-Joubert S; Poupon MF; Servely JL; Fontaine JJ; Liu X; Spooner E; Goodstal S; de Cremoux P; Bièche I; Decaudin D; Marangoni E
Mol Cancer Ther; 2012 Dec; 11(12):2693-703. PubMed ID: 23012245
[TBL] [Abstract][Full Text] [Related]
20. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
